Immutep (IMMP) News Today $2.14 -0.04 (-1.83%) As of 01/6/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average - What's Next?Immutep (NASDAQ:IMMP) Stock Price Crosses Above 50 Day Moving Average - Here's WhyDecember 26, 2024 | marketbeat.comImmutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761December 17, 2024 | globenewswire.comImmutep, Monash University announce publication on human LAG-3December 17, 2024 | markets.businessinsider.comImmutep (NASDAQ:IMMP) Shares Down 4.6% - Here's What HappenedImmutep (NASDAQ:IMMP) Stock Price Down 4.6% - Time to Sell?December 17, 2024 | marketbeat.comImmutep Reveals Promising Data for IMP761 TrialDecember 16, 2024 | tipranks.comImmutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IIDecember 16, 2024 | markets.businessinsider.comImmutep’s Eftilagimod Alpha Shows Promising Results in Head and Neck Cancer Study, Justifying Buy RatingDecember 14, 2024 | markets.businessinsider.comImmutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024December 12, 2024 | globenewswire.comImmutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerDecember 11, 2024 | finance.yahoo.comImmutep Initiates Phase III Trial for Lung CancerDecember 9, 2024 | tipranks.comImmutep: Potential Of Efti As New Standard Of Care For NSCLC PatientsNovember 15, 2024 | seekingalpha.comImmutep (NASDAQ:IMMP) Given New $7.00 Price Target at Robert W. BairdRobert W. Baird raised their target price on shares of Immutep from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday.November 15, 2024 | marketbeat.comImmutep ADRs Climb on Positive Efti Trial ResultsNovember 14, 2024 | marketwatch.comImmutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 14, 2024 | markets.businessinsider.comImmutep Announces Positive Data From INSIGHT-003 Trial In Non-Small Cell Lung Cancer, Stock UpNovember 14, 2024 | markets.businessinsider.comImmutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer TrialNovember 14, 2024 | benzinga.comImmutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 14, 2024 | globenewswire.comImmutep (NASDAQ:IMMP) Stock Price Passes Below Fifty Day Moving Average - Here's What HappenedImmutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average - Here's WhyNovember 8, 2024 | marketbeat.comImmutep Quarterly Activities Report Q1 FY25October 29, 2024 | globenewswire.comImmutep (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?Immutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average - Should You Sell?October 23, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Price Crosses Below 50 Day Moving Average - Should You Sell?Immutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?October 11, 2024 | marketbeat.comAnnovis Bio (NYSE:ANVS) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comImmutep to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comImmutep: Navigating The Bumps In The RoadOctober 7, 2024 | seekingalpha.comImmutep (NASDAQ:IMMP) Share Price Passes Above 50-Day Moving Average of $2.25Immutep (NASDAQ:IMMP) Shares Pass Above 50 Day Moving Average of $2.25September 26, 2024 | marketbeat.comImmutep Receives A$3.6 million R&D Tax Incentive from French GovernmentSeptember 24, 2024 | finance.yahoo.comNew Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue SarcomaSeptember 18, 2024 | markets.businessinsider.comDow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In SeptemberSeptember 16, 2024 | msn.comBuy Rating for Immutep: Promising Developments in Oncology and Competitive EdgeSeptember 16, 2024 | markets.businessinsider.comImmutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerSeptember 16, 2024 | markets.businessinsider.comImmutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerSeptember 16, 2024 | globenewswire.comFY2025 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Increased by AnalystImmutep Limited (NASDAQ:IMMP - Free Report) - Research analysts at Capital One Financial lifted their FY2025 earnings per share estimates for shares of Immutep in a report issued on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotechnology company willSeptember 6, 2024 | marketbeat.comFY2029 EPS Estimates for Immutep Limited Raised by Capital One Financial (NASDAQ:IMMP)Immutep Limited (NASDAQ:IMMP - Free Report) - Analysts at Capital One Financial lifted their FY2029 earnings per share (EPS) estimates for Immutep in a research report issued to clients and investors on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotecSeptember 5, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Short Interest UpdateImmutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 4,730,000 shares, a drop of 10.1% from the July 15th total of 5,260,000 shares. Based on an average trading volume of 372,100 shares, the days-to-cover ratio is presently 12.7 days.August 18, 2024 | marketbeat.comImmutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 AntibodyAugust 14, 2024 | finance.yahoo.comImmutep Quarterly Activities Report Q4 FY24July 31, 2024 | globenewswire.comFY2027 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Lowered by AnalystImmutep Limited (NASDAQ:IMMP - Free Report) - Analysts at Capital One Financial lowered their FY2027 earnings per share (EPS) estimates for shares of Immutep in a note issued to investors on Tuesday, July 16th. Capital One Financial analyst N. Quibria now anticipates that the biotechnology companJuly 19, 2024 | marketbeat.comImmutep Limited Forecasted to Earn FY2029 Earnings of $0.27 Per Share (NASDAQ:IMMP)Immutep Limited (NASDAQ:IMMP - Free Report) - Capital One Financial issued their FY2029 earnings estimates for Immutep in a report issued on Tuesday, July 16th. Capital One Financial analyst N. Quibria forecasts that the biotechnology company will post earnings of $0.27 per share for the year. CaJuly 18, 2024 | marketbeat.comShort Interest in Immutep Limited (NASDAQ:IMMP) Increases By 6.2%Immutep Limited (NASDAQ:IMMP - Get Free Report) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 4,440,000 shares, a growth of 6.2% from the June 15th total of 4,180,000 shares. Based on an average trading volume of 296,400 shares, the days-to-cover ratio is presently 15.0 days.July 17, 2024 | marketbeat.comImmutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 ExpressionJuly 11, 2024 | globenewswire.comImmutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical ResultsJuly 3, 2024 | globenewswire.comImmutep Limited (NASDAQ:IMMP) Short Interest Up 6.6% in JuneImmutep Limited (NASDAQ:IMMP - Get Free Report) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 4,180,000 shares, a growth of 6.6% from the May 31st total of 3,920,000 shares. Based on an average daily trading volume, of 247,200 shares, the days-to-cover ratio is currently 16.9 days.July 3, 2024 | marketbeat.comRobert W. Baird Trims Immutep (NASDAQ:IMMP) Target Price to $6.00Robert W. Baird reduced their price objective on shares of Immutep from $7.00 to $6.00 and set an "outperform" rating on the stock in a research note on Thursday.June 27, 2024 | marketbeat.comImmutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for CancerJune 25, 2024 | globenewswire.comImmutep Limited (NASDAQ:IMMP) Short Interest Up 5.1% in MayImmutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 3,920,000 shares, an increase of 5.1% from the May 15th total of 3,730,000 shares. Based on an average trading volume of 234,100 shares, the short-interest ratio is presently 16.7 days.June 18, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Price Crosses Above 50 Day Moving Average of $2.74Immutep (NASDAQ:IMMP) Share Price Passes Above 50 Day Moving Average of $2.74June 15, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Share Price Crosses Above Fifty Day Moving Average of $2.72Immutep (NASDAQ:IMMP) Shares Cross Above 50-Day Moving Average of $2.72June 7, 2024 | marketbeat.comImmutep successfully completes institutional placement and institutional component of entitlement offerJune 5, 2024 | globenewswire.comImmutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III TrialJune 2, 2024 | globenewswire.comImmutep (NASDAQ:IMMP) Now Covered by Capital One FinancialCapital One Financial initiated coverage on shares of Immutep in a research note on Friday. They set an "overweight" rating and a $10.00 price objective on the stock.May 17, 2024 | marketbeat.com Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Stunning Trump Exec Order Leaked (Ad)Most people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... This could be the most important building in America. Click here and see why. IMMP Media Mentions By Week IMMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMP News Sentiment▼0.000.84▲Average Medical News Sentiment IMMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMP Articles This Week▼01▲IMMP Articles Average Week Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardelyx News Calliditas Therapeutics AB (publ) News Enliven Therapeutics News Syndax Pharmaceuticals News ANI Pharmaceuticals News Rocket Pharmaceuticals News Anavex Life Sciences News ARS Pharmaceuticals News Avadel Pharmaceuticals News Bicycle Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMP) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredTrading 5-7 Stocks to Profit $1,300 a Day?If you want a straightforward, faster, and potentially more reliable way to trade… Learn this strategy by w...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
